<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Gfeller D</submitter><funding>Horizon 2020 Marie Skłodowska-Curie Actions</funding><funding>Swiss Cancer Research Foundation</funding><funding>Swiss Cancer League</funding><funding>Marie Curie</funding><pagination>72-83.e5</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9811684</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>14(1)</volume><pubmed_abstract>The recognition of pathogen or cancer-specific epitopes by CD8&lt;sup>+&lt;/sup> T cells is crucial for the clearance of infections and the response to cancer immunotherapy. This process requires epitopes to be presented on class I human leukocyte antigen (HLA-I) molecules and recognized by the T-cell receptor (TCR). Machine learning models capturing these two aspects of immune recognition are key to improve epitope predictions. Here, we assembled a high-quality dataset of naturally presented HLA-I ligands and experimentally verified neo-epitopes. We then integrated these data in a refined computational framework to predict antigen presentation (MixMHCpred2.2) and TCR recognition (PRIME2.0). The depth of our training data and the algorithmic developments resulted in improved predictions of HLA-I ligands and neo-epitopes. Prospectively applying our tools to SARS-CoV-2 proteins revealed several epitopes. TCR sequencing identified a monoclonal response in effector/memory CD8&lt;sup>+&lt;/sup> T cells against one of these epitopes and cross-reactivity with the homologous peptides from other coronaviruses.</pubmed_abstract><journal>Cell systems</journal><pubmed_title>Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8&lt;sup>+&lt;/sup> T-cell epitopes.</pubmed_title><pmcid>PMC9811684</pmcid><funding_grant_id>101027973</funding_grant_id><funding_grant_id>KFS-4961-02-2020</funding_grant_id><funding_grant_id>H2020-MSCA-IF-2020</funding_grant_id><pubmed_authors>Gfeller D</pubmed_authors><pubmed_authors>Bobisse S</pubmed_authors><pubmed_authors>Genolet R</pubmed_authors><pubmed_authors>Harari A</pubmed_authors><pubmed_authors>Cesbron J</pubmed_authors><pubmed_authors>Queiroz L</pubmed_authors><pubmed_authors>Schmidt J</pubmed_authors><pubmed_authors>Croce G</pubmed_authors><pubmed_authors>Racle J</pubmed_authors><pubmed_authors>Guillaume P</pubmed_authors></additional><is_claimable>false</is_claimable><name>Improved predictions of antigen presentation and TCR recognition with MixMHCpred2.2 and PRIME2.0 reveal potent SARS-CoV-2 CD8&lt;sup>+&lt;/sup> T-cell epitopes.</name><description>The recognition of pathogen or cancer-specific epitopes by CD8&lt;sup>+&lt;/sup> T cells is crucial for the clearance of infections and the response to cancer immunotherapy. This process requires epitopes to be presented on class I human leukocyte antigen (HLA-I) molecules and recognized by the T-cell receptor (TCR). Machine learning models capturing these two aspects of immune recognition are key to improve epitope predictions. Here, we assembled a high-quality dataset of naturally presented HLA-I ligands and experimentally verified neo-epitopes. We then integrated these data in a refined computational framework to predict antigen presentation (MixMHCpred2.2) and TCR recognition (PRIME2.0). The depth of our training data and the algorithmic developments resulted in improved predictions of HLA-I ligands and neo-epitopes. Prospectively applying our tools to SARS-CoV-2 proteins revealed several epitopes. TCR sequencing identified a monoclonal response in effector/memory CD8&lt;sup>+&lt;/sup> T cells against one of these epitopes and cross-reactivity with the homologous peptides from other coronaviruses.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Jan</publication><modification>2026-05-27T23:10:37.047Z</modification><creation>2025-04-04T13:53:28.11Z</creation></dates><accession>S-EPMC9811684</accession><cross_references><pubmed>36603583</pubmed><doi>10.1016/j.cels.2022.12.002</doi></cross_references></HashMap>